Amicus Therapeutics to Host Conference Call Today at 8:00 a.m. ET to Discuss Regulatory Strategy for Migalastat HCl Monotherapy

Amicus Therapeutics to Host Conference Call Today at 8:00 a.m. ET to Discuss
Regulatory Strategy for Migalastat HCl Monotherapy for Fabry Disease

CRANBURY, N.J., June 17, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics
(Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for
rare and orphan diseases, announced that John F. Crowley, Chairman and Chief
Executive Officer, will host a conference call at 8:00 a.m. ET this morning.
Mr. Crowley will highlight the regulatory strategy for migalastat HCl
monotherapy for Fabry disease following a recent Type C meeting with the U.S.
Food and Drug Administration (FDA).

Interested participants and investors may access the conference call this
morning at 8:00 a.m. ET by dialing 877-303-5859 (U.S./Canada) or 678-224-7784
(international). An audio-visual webcast can also be accessed via the
Investors section of the Amicus Therapeutics corporate web site at
http://www.amicusrx.com, and will be archived for 30 days. Web participants
are encouraged to go to the website 15 minutes prior to the start of the call
to register, download and install any necessary software.

A telephonic replay of the call will be available for seven days beginning at
11:00 a.m. ET today. Access numbers for this replay are 855-859-2056
(U.S./Canada) and 404-537-3406 (international); participant code 97032659.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the
forefront of therapies for rare and orphan diseases. The Company is developing
novel, first-in-class treatments for a broad range of human genetic diseases,
with a focus on delivering new benefits to individuals with lysosomal storage
diseases. Amicus' lead programs include the small molecule pharmacological
chaperones migalastat HCl as a monotherapy and in combination with enzyme
replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in
combination with ERT for Pompe disease.

FOLD–G

CONTACT: Investors/Media:
         Sara Pellegrino
         spellegrino@amicusrx.com
         (609) 662-5044
        
         Media:
         Dan Budwick
         dan@purecommunicationsinc.com
         (973) 271-6085
 
Press spacebar to pause and continue. Press esc to stop.